- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of pneumococcal disease in adults
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 504.6KB)
21-valent pneumococcal conjugate vaccine – November 2025
21-valent pneumococcal conjugate vaccine: Injection, 0.5 mL; Capvaxive® - November 2025
Last updated
5 November 2025